Press release Oncology Venture to present a poster at upcoming PARP & DDR Inhibitor Summit on clinical development of 2X-121

NEXT STORY
CORRECTION: Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
PREV STORY
Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial

PLYMOUTH MEETING, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced ...

author_avatar
NASDAQ Market News

ABLYNX TO PRESENT AT UPCOMING USA INVESTOR CONFERENCES

GHENT, Belgium, 16 May 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces ...

author_avatar
NASDAQ Market News

FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Notes into shares

FIT Biotech Oy Company release December 19, 2016at 10:30 am EET Conversion of FIT ...

author_avatar
NASDAQ Market News